Optimization of culture conditions of hESCs for clinical use | References | |
---|---|---|
Elimination of xeno-components | Replacement of mouse feeder layer cells with human feeder layer cells | |
 | Replacement of mouse feeder layer cells with human extracellular matrix | |
 | hESC lines successfully banked under good laboratory practice conditions | |
Scaling up of production of hESCs | Identification of small molecules that promote hESC self-renewal | |
 | Synthetic microcarriers to support hESC culture in suspension |